IL197450A0 - Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors - Google Patents

Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors

Info

Publication number
IL197450A0
IL197450A0 IL197450A IL19745009A IL197450A0 IL 197450 A0 IL197450 A0 IL 197450A0 IL 197450 A IL197450 A IL 197450A IL 19745009 A IL19745009 A IL 19745009A IL 197450 A0 IL197450 A0 IL 197450A0
Authority
IL
Israel
Prior art keywords
biomarkers
prognosis
efficacy
diagnosis
target modulation
Prior art date
Application number
IL197450A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL197450A0 publication Critical patent/IL197450A0/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL197450A 2006-09-19 2009-03-05 Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors IL197450A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84560106P 2006-09-19 2006-09-19
PCT/US2007/078946 WO2008082730A2 (en) 2006-09-19 2007-09-19 Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors

Publications (1)

Publication Number Publication Date
IL197450A0 true IL197450A0 (en) 2009-12-24

Family

ID=39445772

Family Applications (1)

Application Number Title Priority Date Filing Date
IL197450A IL197450A0 (en) 2006-09-19 2009-03-05 Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors

Country Status (13)

Country Link
US (1) US20100004253A1 (https=)
EP (1) EP2074226A2 (https=)
JP (2) JP2010504530A (https=)
KR (1) KR20090071603A (https=)
CN (1) CN101541977A (https=)
AU (1) AU2007340265B2 (https=)
BR (1) BRPI0716944A2 (https=)
CA (1) CA2662508A1 (https=)
IL (1) IL197450A0 (https=)
MX (1) MX2009002936A (https=)
RU (1) RU2009114745A (https=)
SG (1) SG174826A1 (https=)
WO (1) WO2008082730A2 (https=)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
AU2009262022A1 (en) * 2008-06-26 2009-12-30 Dana-Farber Cancer Institute, Inc. Signatures and determinants associated with metastasis and methods of use thereof
WO2010028288A2 (en) 2008-09-05 2010-03-11 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
WO2010056337A2 (en) 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
US20120041274A1 (en) * 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
ES2627911T3 (es) 2009-11-18 2017-08-01 Plexxikon, Inc. Derivados de N-[2-fluoro-3-(4-amino-7H-pirrolo[2,3-d]pirimidin-5-carbonil)-fenil]-4-bencenosulfonamida como moduladores de la proteína quinasa Raf para el tratamiento del cáncer
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
EP2542696B1 (en) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Biomarkers for theranostics
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
US20120045433A1 (en) * 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
EP2619329B1 (en) 2010-09-24 2019-05-22 The Board of Trustees of The Leland Stanford Junior University Direct capture, amplification and sequencing of target dna using immobilized primers
EP2444503B1 (en) * 2010-10-20 2016-03-02 Université Joseph Fourier Use of specific genes for the prognosis of lung cancer and the corresponding progonosis method
CA2815100A1 (en) * 2010-10-21 2012-04-26 Oncotherapy Science, Inc. C18orf54 peptides and vaccines including the same
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
US10260097B2 (en) 2011-06-02 2019-04-16 Almac Diagnostics Limited Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent
SG194800A1 (en) * 2011-06-02 2013-12-30 Novartis Ag Biomarkers for hedgehog inhibitor therapy
US20140302042A1 (en) * 2011-07-01 2014-10-09 Dana-Farber Cancer Institute, Inc. Methods of predicting prognosis in cancer
US10378060B2 (en) 2011-10-14 2019-08-13 Dana-Farber Cancer Institute, Inc. ZNF365/ZFP365 biomarker predictive of anti-cancer response
EP2788378A4 (en) * 2011-12-09 2015-09-09 Oncomed Pharm Inc COMBINATION THERAPY FOR CANCER TREATMENT
JP6192123B2 (ja) * 2012-01-09 2017-09-06 スージョウ マイクロダイアグ バイオメディスン カンパニー リミテッド 乳癌の予測および診断のためのバイオマーカー
WO2013148147A1 (en) 2012-03-26 2013-10-03 The U.S.A., As Represented By The Secretary Dept. Of Health And Human Services Dna methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
KR20190057421A (ko) 2012-08-17 2019-05-28 에프. 호프만-라 로슈 아게 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
TWI601725B (zh) * 2012-08-27 2017-10-11 加拓科學公司 取代的氮雜吲哚化合物及其鹽、組合物和用途
WO2014055775A1 (en) * 2012-10-03 2014-04-10 Exosome Diagnostics, Inc. Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions
SG11201504023SA (en) 2012-12-03 2015-06-29 Almac Diagnostics Ltd Molecular diagnostic test for cancer
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
MX2015014486A (es) * 2013-04-15 2016-07-21 Regeneron Pharma Marcadores de respuesta de células tumorales a la terapia.
CN103941016B (zh) * 2013-05-07 2016-04-27 上海良润生物医药科技有限公司 半胱氨酸蛋白酶抑制剂sn与癌胚抗原的联合应用
US20160116480A1 (en) * 2013-05-13 2016-04-28 Institut Gustave Roussy Prognosis and predictive biomarkers and biological applications thereof
ES2813877T3 (es) * 2013-08-28 2021-03-25 Crown Bioscience Inc Taicang Distintivos de expresión génica predictivos de la respuesta de un sujeto a un inhibidor multicinasa y métodos de uso de los mismos
EP3074536B1 (en) 2013-11-25 2019-06-19 Children's Hospital Medical Center Temporal pediatric sepsis biomarker risk model
WO2015085172A2 (en) 2013-12-06 2015-06-11 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
SG11201604664PA (en) * 2013-12-12 2016-07-28 Stemcentrx Inc Novel anti-dpep3 antibodies and methods of use
US10545144B2 (en) 2013-12-31 2020-01-28 Yeda Research And Development Co., Ltd. Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
ES2727374T3 (es) * 2014-04-04 2019-10-15 Crown Bioscience Inc Taicang Gen de fusión HNF4G-RSPO2
GB201408100D0 (en) * 2014-05-07 2014-06-18 Sec Dep For Health The Detection method
WO2016011065A1 (en) * 2014-07-15 2016-01-21 Salk Institute For Biolofical Studies Detecting dixdc1 (dix domain-containing protein 1) expression to determine if a tumor will respond to fak and src kinase inhibitors
JP2017533727A (ja) * 2014-10-13 2017-11-16 セルジーン コーポレイション 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用
CN104502603B (zh) * 2014-12-03 2016-04-06 上海交通大学医学院附属上海儿童医学中心 Myo1d作为诊断动脉导管闭合或开放的标志物
CN105986023B (zh) * 2015-02-17 2021-01-05 上海交通大学医学院附属上海儿童医学中心 急性淋巴细胞白血病耐药复发相关突变基因及其应用
WO2016131420A1 (zh) 2015-02-17 2016-08-25 上海交通大学医学院附属上海儿童医学中心 急性淋巴细胞白血病耐药复发相关突变基因及其应用
EP3265814B1 (en) 2015-03-01 2020-11-18 Immunarray Ltd. Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
CN105063183A (zh) * 2015-07-22 2015-11-18 浙江理工大学 泛素化途径相关基因在作为用于预测乳腺癌新辅助化疗疗效的生物标记物的应用
US20180231565A1 (en) * 2015-08-09 2018-08-16 Immunarray Ltd Methods for determining the risk of a systemic lupus erythematosus (sle) patient to develop neuropsychiatric syndromes
US20180231561A1 (en) * 2015-08-12 2018-08-16 Celgene Corporation Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
CN105126080A (zh) * 2015-09-29 2015-12-09 武汉大学 锌指蛋白436（znf436）在治疗心肌肥厚中的应用
CN105671158B (zh) * 2016-02-29 2019-01-18 北京泱深生物信息技术有限公司 Fam63b基因在制备诊治子宫肌瘤的产品中的用途
KR20180134347A (ko) * 2016-04-15 2018-12-18 제넨테크, 인크. 암의 진단 및 치료 방법
CN105695617A (zh) * 2016-04-22 2016-06-22 王冬国 乳头状癌的肿瘤标志物及其应用
EP4219767A1 (en) * 2016-06-17 2023-08-02 F. Hoffmann-La Roche AG Papd5 and papd7 inhibitors for treating a hepatitis b infection
US10519113B2 (en) * 2016-08-17 2019-12-31 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds, compositions, and methods of treating cancer
CN108300783A (zh) * 2017-01-11 2018-07-20 上海易毕恩基因科技有限公司 用于筛选肠癌和/或胃癌的基因标志物的方法、用该方法筛选的基因标志物及其用途
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
CA3056389A1 (en) * 2017-03-15 2018-09-20 Eisai R&D Management Co., Ltd. Spliceosome mutations and uses thereof
CN109081866B (zh) * 2017-06-13 2021-07-16 北京大学 癌症中的t细胞亚群及其特征基因
CN113683700B (zh) * 2017-06-22 2023-05-02 北海康成（北京）医药科技有限公司 预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒
CN111511914B (zh) 2017-10-16 2023-11-17 豪夫迈·罗氏有限公司 减少PAPD5和PAPD7 mRNA的核酸分子用于治疗乙型肝炎感染
CN109825508A (zh) * 2017-11-23 2019-05-31 深圳市第三人民医院 一种用来评估艾滋病合并结核感染的生物标记物
CN109870576B (zh) * 2017-12-05 2021-08-10 中国科学院大连化学物理研究所 Usp10蛋白的定量检测在原发性肝癌预后判断试剂盒中的应用
US12054558B2 (en) * 2018-05-23 2024-08-06 The Jackson Laboratory Anti-NGly-1 antibodies and methods of use
CN108707628B (zh) * 2018-05-28 2021-11-23 上海海洋大学 斑马鱼notch2基因突变体的制备方法
CN108753834B (zh) * 2018-05-28 2021-11-23 上海海洋大学 ddx27基因缺失斑马鱼突变体的制备方法
CN108676867B (zh) * 2018-06-06 2020-06-09 青岛泱深生物医药有限公司 诊治子痫前期的vwce基因及其应用
CN108624678B (zh) * 2018-06-26 2020-07-17 青岛泱深生物医药有限公司 一种用于子痫前期诊治的生物标志物
CN108841960B (zh) * 2018-07-12 2022-02-01 吉林大学 一种结肠腺癌易感性预测试剂盒及系统
CN109468320A (zh) * 2018-11-13 2019-03-15 复旦大学附属中山医院 一种环状rna及其在肝癌诊断中的应用
WO2020117715A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment
CN111467493A (zh) * 2019-01-23 2020-07-31 首都师范大学 人rev3l蛋白切割抑制剂及其应用
CN111896740B (zh) * 2019-05-06 2025-02-11 山东大学 诊断或预测生育缺陷的试剂盒
EP4039801A4 (en) * 2019-08-16 2023-10-18 Center For Excellence In Brain Science And Intelligence Technology, Chinese Academy Of Sciences USE OF PTBP1 INHIBITORS TO PREVENT AND/OR TREAT NERVOUS SYSTEM DISEASES ASSOCIATED WITH FUNCTIONAL NEURONAL DEATH
CN110551819B (zh) * 2019-08-23 2023-05-16 伯克利南京医学研究有限责任公司 一组卵巢癌预后相关基因的应用
CN110408706B (zh) * 2019-08-30 2023-04-11 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种评估鼻咽癌复发的生物标志物及其应用
CN110643571B (zh) * 2019-10-22 2021-07-27 康妍葆(北京)干细胞科技有限公司 人角蛋白6a在干细胞培养中的应用及产品
KR102261606B1 (ko) * 2019-11-07 2021-06-07 (주)지노믹트리 대장암 검출 방법
CN110819714B (zh) * 2019-11-22 2023-01-10 南方医科大学深圳医院 一种抑癌基因及其应用
US12287338B2 (en) 2019-11-27 2025-04-29 Ascentage Pharma (Suzhou) Co., Ltd. Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway
US20230220391A1 (en) * 2020-06-09 2023-07-13 Genethon CILP-1 Inhibitors for Use in the Treatment of Dilated Cardiomyopathies
CN111781358A (zh) * 2020-07-13 2020-10-16 张瑜 Xab2蛋白作为卵巢癌预后和/或预测铂类耐药标志物
CN113943798B (zh) * 2020-07-16 2023-10-27 中国农业大学 一种circ RNA作为肝细胞癌诊断标志物及治疗靶点的应用
EP4217378A4 (en) * 2020-10-08 2025-02-26 The Trustees Of Dartmouth College Methods and agents for treating, preventing, diagnosing, and evaluating therapy for fibrotic, autoimmune, and inflammatory conditions
CN112816708B (zh) * 2021-02-02 2022-05-31 中南大学湘雅二医院 一种预测食管鳞癌患者对化疗药物敏感性的蛋白指标及应用
CN112691195B (zh) * 2021-02-02 2023-03-14 黑龙江省科学院高技术研究院 Prpf8表达抑制剂在制备治疗肺癌的药物中的应用
CN112816711B (zh) * 2021-03-17 2024-04-19 中国医科大学附属盛京医院 用于神经管畸形、先天性心脏病和唇腭裂胎儿产前无创诊断的分子标志物及其应用
CN113373220A (zh) * 2021-05-08 2021-09-10 首都医科大学 与非小细胞肺癌预后相关的标志分子
CN113416739B (zh) * 2021-06-24 2022-04-19 黑龙江八一农垦大学 鲁氏酵母菌基因在提高微生物产hdmf的产量中的应用
CN113667749A (zh) * 2021-08-03 2021-11-19 广东省人民医院 四个关键基因组合评估乳腺癌风险的诊断试剂盒
CN113866424A (zh) * 2021-09-14 2021-12-31 哈尔滨医科大学 碳酸酐酶1和酸性鞘磷脂酶样磷酸二酯酶3a作为分子标志物在结直肠癌诊断中的应用
CN113897437B (zh) * 2021-11-30 2024-06-04 深圳市人民医院 检测样本中标志物表达水平的试剂在制备用于诊断乳腺癌的试剂盒中的应用
CN114592059A (zh) * 2022-01-11 2022-06-07 南方医科大学南方医院 一种评估5-fu治疗敏感性/耐药性的试剂盒
CN114525342B (zh) * 2022-03-03 2025-02-14 温州医科大学附属第一医院 Linc02806在肝细胞癌诊断和治疗中的应用
WO2023174378A1 (zh) * 2022-03-16 2023-09-21 南京施江医药科技有限公司 一种含氮杂环类化合物
CN114672551B (zh) * 2022-05-17 2023-03-31 中国医科大学附属第一医院 Mat2a和mat2b作为检测或治疗良性前列腺增生的药物靶点的应用
CN115389764A (zh) * 2022-07-28 2022-11-25 宁波大学 蛋白质fbxo7在制备子宫内膜癌诊断标志物中的应用
CN115948529A (zh) * 2022-08-01 2023-04-11 湖南家辉生物技术有限公司 一种Cornelia de Lange综合征1型的致病基因、引物对及其应用
CN116179691A (zh) * 2022-09-07 2023-05-30 苏州大学附属第一医院 一种胃癌组合标志物及标志物模型的建立方法
WO2024107924A2 (en) * 2022-11-17 2024-05-23 Board Of Regents, The University Of Texas System A blood-based lipid biomarker panel for personalized risk assessment of breast cancer
CN115948537B (zh) * 2022-12-19 2024-04-09 湖南家辉生物技术有限公司 一种基因chst3复合杂合突变的应用及检测试剂和应用
CN116287253B (zh) * 2023-02-22 2024-06-28 武汉科技大学 一种肺癌分子标志物及其应用
CN116500266B (zh) * 2023-03-07 2025-06-17 南通大学附属医院 MRPS21基因及其RNAi干扰系统的应用
CN116430048B (zh) * 2023-03-07 2025-06-20 南通大学附属医院 BTF3L4基因及其RNAi干扰系统的应用
CN117100866B (zh) * 2023-03-31 2025-10-28 兰州大学第二医院 一种抗肿瘤血管生成药物增效剂、抗肿瘤药物组合物及应用
CN116769916B (zh) * 2023-06-27 2025-03-07 南通大学附属医院 Tmed8基因在制备胰腺癌药物及其诊断试剂盒中的应用
CN116747215A (zh) * 2023-07-14 2023-09-15 新疆医科大学第三附属医院 V-9302在抑制肝癌和增强索拉菲尼抑癌作用中的应用
CN117257919B (zh) * 2023-11-10 2024-10-01 南通大学附属医院 Tbc1d15在筛选或制备保护肝脏的药物中的应用
CN117821469B (zh) * 2023-11-22 2024-08-02 扬州大学 一种鸡trim45截短体重组蛋白或其多克隆抗体的应用
CN118045083B (zh) * 2024-04-15 2024-06-18 哈尔滨医科大学 L-脯氨酸在制备防治非酒精性脂肪肝病药物中的新用途
CN118879858B (zh) * 2024-06-27 2025-09-30 中国科学院合肥物质科学研究院 一组用于预测非小细胞肺癌放疗预后的基因标签及应用
CN120636556A (zh) * 2025-05-07 2025-09-12 武汉科技大学 一种筛选转录调控元件的方法及其应用
CN120442707B (zh) * 2025-07-14 2025-09-09 三亚中国农业科学院国家南繁研究院 棉花耐旱性和耐低温性相关蛋白GhCOX11及其应用
CN121559090B (zh) * 2026-01-08 2026-04-17 山东大学 完全性葡萄胎的生物标志物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US20030119769A1 (en) * 1994-05-31 2003-06-26 Monia Brett P Antisense oligonucleotide modulation of raf gene expression
US6358932B1 (en) * 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) * 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
JP2000511419A (ja) * 1996-05-23 2000-09-05 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ Ｒａｆ―１または１４―３―３タンパク質のＩＬ―２受容体β鎖への結合を阻害する化合物およびそれを含有する医薬組成物
AR012634A1 (es) * 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6187799B1 (en) * 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
ME00275B (me) * 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
US6610484B1 (en) * 1999-01-26 2003-08-26 Cytyc Health Corporation Identifying material from a breast duct
US20040018570A1 (en) * 1999-09-01 2004-01-29 Brown University Kinase inhibitors and methods of use in screening assays and modulation of cell proliferation and growth
WO2004087941A1 (en) * 2002-02-15 2004-10-14 The General Hospital Corporation Map-kinase inhibitors as regulators of tumor-associated antigen expression
US20040224302A1 (en) * 2002-07-16 2004-11-11 Thomas Jessel Systems and methods for screening for modulators of neural differentiation
EP1575417A4 (en) * 2002-09-30 2007-07-04 Bayer Pharmaceuticals Corp CANCER FORECASTING AND PROGNOSTIC TECHNIQUES AND SURVEILLANCE OF ANTICANCER THERAPY
EP2311985A1 (en) * 2005-07-27 2011-04-20 Oncotherapy Science, Inc. Sirna for treating esophageal cancer
TWI387592B (zh) * 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法

Also Published As

Publication number Publication date
MX2009002936A (es) 2009-04-01
US20100004253A1 (en) 2010-01-07
JP2013128487A (ja) 2013-07-04
BRPI0716944A2 (pt) 2013-09-17
KR20090071603A (ko) 2009-07-01
WO2008082730A3 (en) 2009-01-08
CN101541977A (zh) 2009-09-23
AU2007340265B2 (en) 2012-07-26
WO2008082730A2 (en) 2008-07-10
EP2074226A2 (en) 2009-07-01
RU2009114745A (ru) 2010-10-27
SG174826A1 (en) 2011-10-28
CA2662508A1 (en) 2008-07-10
AU2007340265A1 (en) 2008-07-10
JP2010504530A (ja) 2010-02-12

Similar Documents

Publication Publication Date Title
IL197450A0 (en) Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
IL223419A0 (en) Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
PL1999136T3 (pl) Peptydomimetyczne inhibitory PSMA, związki je zawierające i sposoby ich zastosowania
BRPI0720695A2 (pt) Compostos e métodos para modulação de cinase, e indicações para estes
GB0619753D0 (en) Enzyme inhibitors
IL185189A0 (en) Methods and systems for diagnosis, prognosis and selection of treatment of leukemia
ZA200810025B (en) Cox-2 inhibitor
IL187859A0 (en) Diagnosis and prognosis of diabetes
IL194339A0 (en) Enzyme inhibitors
GB2439865B (en) Method for evaluating the reliability of steel
ZA200808669B (en) Methods of treating, diagnosing or detecting cancer
IL193335A0 (en) Method for geolocalization of one or more targets
WO2008115710A3 (en) Biomarkers for cancer
IT1398375B1 (it) Metodo e kit per la prevenzione e/o monitoraggio della chemioresistenza di forme leucemiche.
WO2009098451A3 (en) Biomarkers of aminopeptidase inhibition
GB0624187D0 (en) HDAC inhibitors
ZA200900636B (en) Method of prognosis
GB0617161D0 (en) Enzyme inhibitors
WO2007147525A3 (en) Fbpase co-crystals
PL2044186T3 (pl) Inhibitory korozji oparte na tetraoksowolframianie(VI)
HK1129901A (en) Amigo-2 inhibitors for treating, diagnosing or detecting cancer
GB0710768D0 (en) Method of identifying biomarkers
GB0620884D0 (en) Enzyme inhibitors
ZA200808237B (en) Enzyme inhibitors
GB0612544D0 (en) Enzyme inhibitors